S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
NASDAQ:AMPH

Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis

$53.41
+1.50 (+2.89%)
(As of 02/23/2024 ET)
Today's Range
$51.91
$53.55
50-Day Range
$51.25
$63.45
52-Week Range
$31.86
$67.66
Volume
289,060 shs
Average Volume
410,273 shs
Market Capitalization
$2.56 billion
P/E Ratio
20.86
Dividend Yield
N/A
Price Target
$68.00

Amphastar Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
27.3% Upside
$68.00 Price Target
Short Interest
Bearish
8.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.21
Upright™ Environmental Score
News Sentiment
0.57mentions of Amphastar Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$15.60 M Sold Last Quarter
Proj. Earnings Growth
20.27%
From $2.91 to $3.50 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.94 out of 5 stars

Medical Sector

22nd out of 942 stocks

Pharmaceutical Preparations Industry

10th out of 429 stocks


AMPH stock logo

About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

AMPH Stock Price History

AMPH Stock News Headlines

Amphastar Pharmaceuticals, Inc.
Claim Your FREE Ultimate Dividend Package (Seriously, put your wallet away!)
Amphastar- Five Star Trade in Biotech
Amphastar Pharmaceuticals Inc.
Claim Your FREE Ultimate Dividend Package (Seriously, put your wallet away!)
3 Pharma Stocks to Watch in 2024 for Later Gains
See More Headlines
Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
2/24/2024
Next Earnings (Estimated)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AMPH
Employees
1,615
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$68.00
High Stock Price Target
$71.00
Low Stock Price Target
$63.00
Potential Upside/Downside
+27.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$91.39 million
Pretax Margin
28.48%

Debt

Sales & Book Value

Annual Sales
$498.99 million
Cash Flow
$2.43 per share
Book Value
$10.94 per share

Miscellaneous

Free Float
34,301,000
Market Cap
$2.56 billion
Optionable
Optionable
Beta
0.90
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives















AMPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Amphastar Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AMPH shares.
View AMPH analyst ratings
or view top-rated stocks.

What is Amphastar Pharmaceuticals' stock price target for 2024?

2 brokerages have issued 1 year price objectives for Amphastar Pharmaceuticals' stock. Their AMPH share price targets range from $63.00 to $71.00. On average, they anticipate the company's stock price to reach $68.00 in the next twelve months. This suggests a possible upside of 27.3% from the stock's current price.
View analysts price targets for AMPH
or view top-rated stocks among Wall Street analysts.

How have AMPH shares performed in 2024?

Amphastar Pharmaceuticals' stock was trading at $61.85 on January 1st, 2024. Since then, AMPH shares have decreased by 13.6% and is now trading at $53.41.
View the best growth stocks for 2024 here
.

When is Amphastar Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our AMPH earnings forecast
.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced its quarterly earnings data on Monday, November, 8th. The company reported $0.46 EPS for the quarter, beating the consensus estimate of $0.24 by $0.22. The company had revenue of $112.20 million for the quarter, compared to the consensus estimate of $103 million. Amphastar Pharmaceuticals had a net margin of 22.50% and a trailing twelve-month return on equity of 26.68%. During the same period last year, the business posted $0.09 earnings per share.

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?

35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend.

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Federated Hermes Inc. (6.83%), Vanguard Group Inc. (5.88%), Dimensional Fund Advisors LP (2.80%), TD Asset Management Inc (1.66%), Epoch Investment Partners Inc. (1.24%) and Price T Rowe Associates Inc. MD (1.23%). Insiders that own company stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Mary Z Luo, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters and Yakob Liawatidewi.
View institutional ownership trends
.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMPH) was last updated on 2/24/2024 by MarketBeat.com Staff